First-in-primate data demonstrate in vivo generation of genomic site-specific engineered TRAC-CAR T cells following a single intravenous administration without lymphodepletionAll non-human primates (6 of 6) exhibited deep B cell depletion in peripheral blood by Day 10Potent B cell clearance observed across peripheral blood, lymph nodes and bone marrowTreatment was generally well tolerated, with no deaths, no neurotoxicity and no off-target CAR expression or integration detected in non-T cells in the blood BERKELEY, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced that first-in-primate data from its proprietary in vivo CAR T cell platform have been accepted as a late-breaking abstract for oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11 - 15, 2026 in Boston, Massachusetts.